We found that dietary cholesterol intake was linearly associated with greater risk of MI. These findings contribute to the growing literature highlighting the impact dietary cholesterol has on cardiovascular health. Reductions in cholesterol intake, which can be achieved by decreasing the intake of meat and eggs, may reduce the risk of incident MI.

Higher mortality risk was generally attributed to higher dietary AGEs in patients with cirrhosis.

New research reveals that microplastics, especially those from food containers, can damage blood vessels, triggering inflammation and cellular changes linked to cardiovascular disease.

Coenzyme Q10 supplementation appears to have a beneficial effect on lipid profiles and may contribute to lowering blood pressure in patients with Type 2 Diabetes. These findings suggest that CoQ10 could be a valuable adjunctive therapy for managing cardiovascular risk in this population.

Higher niacin consumption was correlated with a decreased risk of cardiovascular disease and death from all causes across the entire study population

According to the U.S. Physician Workforce Data Dashboard, only about 17% of cardiologists are women, ranking as one of the lowest specialties among female physicians, yet heart disease remains the number one killer of women, accounting for one in five female deaths. El Camino Health is innovating a solution to address the unique symptoms and risk factors of heart disease in women.

For the first time, we show that acute ketone monoester ingestion (K_me) can increase cardiac output and stroke volume and reduce systemic vascular resistance at rest and during exercise in sodium glucose transporter inhibitors naïve (i.e. no drug-induced ketosis) people with type 2 diabetes.

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart attack and stroke among these patients, according to results from an international clinical trial led by a Mount Sinai researcher.

Sotagliflozin is a sodium-glucose cotransporter (SGLT) inhibitor. It blocks the function of two proteins, known as SGLT1 and SGLT2, which move glucose and sodium across cell membranes and help control blood sugar levels. Other SGLT2 inhibitors do not as significantly block SGLT1.